UBS Group’s Applied Therapeutics APLT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-718,924
| Closed | -$71.9K | – | 10445 |
|
|
2025
Q4 | $71.9K | Sell |
718,924
-1,186,701
| -62% | -$754K | ﹤0.01% | 7057 |
|
|
2025
Q3 | $1.15M | Buy |
1,905,625
+1,074,980
| +129% | +$506K | ﹤0.01% | 5445 |
|
|
2025
Q2 | $258K | Buy |
830,645
+325,538
| +64% | +$126K | ﹤0.01% | 6548 |
|
|
2025
Q1 | $247K | Buy |
505,107
+63,338
| +14% | +$37.3K | ﹤0.01% | 6392 |
|
|
2024
Q4 | $378K | Buy |
441,769
+158,084
| +56% | +$991K | ﹤0.01% | 6038 |
|
|
2024
Q3 | $2.41M | Buy |
283,685
+111,622
| +65% | +$658K | ﹤0.01% | 3818 |
|
|
2024
Q2 | $804K | Buy |
172,063
+19,303
| +13% | +$91.3K | ﹤0.01% | 4617 |
|
|
2024
Q1 | $1.04M | Buy |
152,760
+32,553
| +27% | +$146K | ﹤0.01% | 4568 |
|
|
2023
Q4 | $403K | Buy |
120,207
+11,826
| +11% | +$29.4K | ﹤0.01% | 5270 |
|
|
2023
Q3 | $270K | Buy |
108,381
+1,738
| +2% | +$2.87K | ﹤0.01% | 5147 |
|
|
2023
Q2 | $137K | Buy |
106,643
+32,942
| +45% | +$43.7K | ﹤0.01% | 5765 |
|
|
2023
Q1 | $59.8K | Buy |
73,701
+62,333
| +548% | +$61.4K | ﹤0.01% | 6318 |
|
|
2022
Q4 | $8.64K | Sell |
11,368
-15,781
| -58% | -$12.5K | ﹤0.01% | 8749 |
|
|
2022
Q3 | $26K | Buy |
27,149
+1,286
| +5% | +$1.54K | ﹤0.01% | 7034 |
|
|
2022
Q2 | $24K | Buy |
25,863
+3,850
| +17% | +$6.3K | ﹤0.01% | 6639 |
|
|
2022
Q1 | $47K | Sell |
22,013
-52,408
| -70% | -$140K | ﹤0.01% | 6554 |
|
|
2021
Q4 | $666K | Buy |
74,421
+53,211
| +251% | +$699K | ﹤0.01% | 4746 |
|
|
2021
Q3 | $352K | Sell |
21,210
-1,075
| -5% | -$18.6K | ﹤0.01% | 4948 |
|
|
2021
Q2 | $463K | Sell |
22,285
-4,355
| -16% | -$82.4K | ﹤0.01% | 4787 |
|
|
2021
Q1 | $500K | Buy |
26,640
+2,359
| +10% | +$50.9K | ﹤0.01% | 4867 |
|
|
2020
Q4 | $535K | Sell |
24,281
-78,409
| -76% | -$1.63M | ﹤0.01% | 4549 |
|
|
2020
Q3 | $2.13M | Buy |
102,690
+20,450
| +25% | +$532K | ﹤0.01% | 2981 |
|
|
2020
Q2 | $2.97M | Buy |
82,240
+77,205
| +1,533% | +$3.23M | ﹤0.01% | 2507 |
|
|
2020
Q1 | $164K | Sell |
5,035
-5,190
| -51% | -$210K | ﹤0.01% | 4878 |
|
|
2019
Q4 | $279K | Buy |
10,225
+6,482
| +173% | +$111K | ﹤0.01% | 5346 |
|
|
2019
Q3 | $41K | Buy |
3,743
+1,599
| +75% | +$15.1K | ﹤0.01% | 6300 |
|
|
2019
Q2 | $18K | Buy |
+2,144
| New | +$20.3K | ﹤0.01% | 6677 |
|
UBS Group's APLT Position: Q1 2026 in Review
UBS Group sold out of Applied Therapeutics (APLT) in Q1 2026, closing a stake of 718,924 shares — an estimated $71.9K sold.
UBS Group first reported a position in APLT in Q2 2019 and held it in 27 quarters. The position peaked at $2.97M in Q2 2020. 0 funds tracked by Wall St. Rank hold APLT as of Q1 2026.
- UBS Group reported no remaining Applied Therapeutics position as of Q1 2026 after selling out during the quarter.
- UBS Group sold 718,924 Applied Therapeutics shares in Q1 2026, an estimated $71.9K.
- UBS Group first reported a position in Applied Therapeutics in Q2 2019 and held it in 27 quarters.
- UBS Group's Applied Therapeutics position peaked at $2.97M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Applied Therapeutics as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.